MedTrace Logo

EKOS in Patients With Pulmonary Embolism (PE)

NCT06738108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2025-01-09

No results posted yet for this study

Summary

A retrospective cohort study assessed patients who underwent EKOS intervention following the failure of initial therapeutic anticoagulation for managing acute pulmonary embolism at a tertiary hospital.

Conditions

Interventions

DRUG

ECOS

The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE

DRUG

Control group

Alteplase IV infusion

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-13
Primary Completion
2024-12-20
Completion
2025-01-08

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738108 on ClinicalTrials.gov